APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vulvar and Vaginal Atrophy Therapy

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vulvar and Vaginal Atrophy Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025184 pages

Choose your research edition.

Industry ResearchVulvar and Vaginal Atrophy Therapy Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Vulvar and Vaginal Atrophy Therapy Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Vulvar and Vaginal Atrophy Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vulvar and Vaginal Atrophy Therapy Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Vulvar and Vaginal Atrophy Therapy Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Vulvar and Vaginal Atrophy Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vulvar and Vaginal Atrophy Therapy include Viveve, VenusConcept, ThermiGen LLC, Lutronic, Hologic, Fotona, BTL Group of Companies, Almirall and Alma Lasers, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vulvar and Vaginal Atrophy Therapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vulvar and Vaginal Atrophy Therapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vulvar and Vaginal Atrophy Therapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vulvar and Vaginal Atrophy Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Vulvar and Vaginal Atrophy Therapy Segment by Company

Viveve

VenusConcept

ThermiGen LLC

Lutronic

Hologic

Fotona

BTL Group of Companies

Almirall

Alma Lasers

Vulvar and Vaginal Atrophy Therapy Segment by Type

Vulvar Atrophy Therapy

Vaginal Atrophy Therapy

Vulvar and Vaginal Atrophy Therapy Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Others

Vulvar and Vaginal Atrophy Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vulvar and Vaginal Atrophy Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vulvar and Vaginal Atrophy Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vulvar and Vaginal Atrophy Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vulvar and Vaginal Atrophy Therapy market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vulvar and Vaginal Atrophy Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vulvar and Vaginal Atrophy Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vulvar and Vaginal Atrophy Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vulvar and Vaginal Atrophy Therapy Industry Trends Table 2. Vulvar and Vaginal Atrophy Therapy Industry Drivers Table 3. Vulvar and Vaginal Atrophy Therapy Industry Opportunities and Challenges Table 4. Vulvar and Vaginal Atrophy Therapy Industry Restraints Table 5. Global Vulvar and Vaginal Atrophy Therapy Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vulvar and Vaginal Atrophy Therapy Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Manufacturers Table 9. Global Vulvar and Vaginal Atrophy Therapy Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vulvar and Vaginal Atrophy Therapy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vulvar and Vaginal Atrophy Therapy Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vulvar and Vaginal Atrophy Therapy Manufacturers, Product Type & Application Table 13. Global Vulvar and Vaginal Atrophy Therapy Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vulvar and Vaginal Atrophy Therapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Vulvar Atrophy Therapy Table 17. Major Manufacturers of Vaginal Atrophy Therapy Table 18. Global Vulvar and Vaginal Atrophy Therapy Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2026) & (K Units) Table 20. Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2027-2032) & (K Units) Table 21. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2021-2026) Table 22. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2027-2032) Table 23. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2026) & (K Units) Table 25. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2027-2032) & (K Units) Table 26. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2021-2026) Table 27. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Specialty Clinics Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Ambulatory Surgical Centers Table 31. Major Manufacturers of Others Table 32. Global Vulvar and Vaginal Atrophy Therapy Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2026) & (K Units) Table 34. Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2027-2032) & (K Units) Table 35. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2021-2026) Table 36. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2027-2032) Table 37. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2026) & (K Units) Table 39. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2027-2032) & (K Units) Table 40. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2021-2026) Table 41. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2027-2032) Table 42. Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2021-2026) & (K Units) Table 44. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Region (2021-2026) Table 45. Global Vulvar and Vaginal Atrophy Therapy Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Vulvar and Vaginal Atrophy Therapy Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 49. North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 50. Europe Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 52. Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales by Country (2027-2032) & (K Units) Table 59. Global Vulvar and Vaginal Atrophy Therapy Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region (2021-2026) Table 63. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region (2027-2032) Table 64. Viveve Company Information Table 65. Viveve Business Overview Table 66. Viveve Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Viveve Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 68. Viveve Recent Development Table 69. VenusConcept Company Information Table 70. VenusConcept Business Overview Table 71. VenusConcept Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. VenusConcept Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 73. VenusConcept Recent Development Table 74. ThermiGen LLC Company Information Table 75. ThermiGen LLC Business Overview Table 76. ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 78. ThermiGen LLC Recent Development Table 79. Lutronic Company Information Table 80. Lutronic Business Overview Table 81. Lutronic Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Lutronic Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 83. Lutronic Recent Development Table 84. Hologic Company Information Table 85. Hologic Business Overview Table 86. Hologic Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Hologic Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 88. Hologic Recent Development Table 89. Fotona Company Information Table 90. Fotona Business Overview Table 91. Fotona Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Fotona Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 93. Fotona Recent Development Table 94. BTL Group of Companies Company Information Table 95. BTL Group of Companies Business Overview Table 96. BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 98. BTL Group of Companies Recent Development Table 99. Almirall Company Information Table 100. Almirall Business Overview Table 101. Almirall Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Almirall Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 103. Almirall Recent Development Table 104. Alma Lasers Company Information Table 105. Alma Lasers Business Overview Table 106. Alma Lasers Vulvar and Vaginal Atrophy Therapy Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Alma Lasers Vulvar and Vaginal Atrophy Therapy Product Portfolio Table 108. Alma Lasers Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Vulvar and Vaginal Atrophy Therapy Distributors List Table 112. Vulvar and Vaginal Atrophy Therapy Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Vulvar and Vaginal Atrophy Therapy Product Image Figure 2. Global Vulvar and Vaginal Atrophy Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vulvar and Vaginal Atrophy Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Vulvar and Vaginal Atrophy Therapy Sales (2021-2032) & (K Units) Figure 5. Global Vulvar and Vaginal Atrophy Therapy Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vulvar and Vaginal Atrophy Therapy Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Vulvar Atrophy Therapy Image Figure 9. Vaginal Atrophy Therapy Image Figure 10. Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2021-2032) Figure 13. Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2021-2032) Figure 16. Specialty Clinics Image Figure 17. Hospitals Image Figure 18. Ambulatory Surgical Centers Image Figure 19. Others Image Figure 20. Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2021-2032) Figure 23. Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2021-2032) Figure 26. North America Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Vulvar and Vaginal Atrophy Therapy Sales Market Share by Country (2021-2032) Figure 28. U.S. Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Vulvar and Vaginal Atrophy Therapy Sales Market Share by Country (2021-2032) Figure 33. Germany Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales Market Share by Country (2021-2032) Figure 40. China Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales Market Share by Country (2021-2032) Figure 48. Brazil Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Vulvar and Vaginal Atrophy Therapy Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Vulvar and Vaginal Atrophy Therapy Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Figure 59. North America Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Figure 61. Europe Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Vulvar and Vaginal Atrophy Therapy Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Vulvar and Vaginal Atrophy Therapy Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Vulvar Atrophy Therapy
  • Vaginal Atrophy Therapy
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Viveve
  • VenusConcept
  • ThermiGen LLC
  • Lutronic
  • Hologic
  • Fotona
  • BTL Group of Companies
  • Almirall
  • Alma Lasers

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vulvar and Vaginal Atrophy Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vulvar and Vaginal Atrophy Therapy Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vulvar and Vaginal Atrophy Therapy Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vulvar and Vaginal Atrophy Therapy Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vulvar and Vaginal Atrophy Therapy Market Dynamics
  1. 2.1 Vulvar and Vaginal Atrophy Therapy Industry Trends
  2. 2.2 Vulvar and Vaginal Atrophy Therapy Industry Drivers
  3. 2.3 Vulvar and Vaginal Atrophy Therapy Industry Opportunities and Challenges
  4. 2.4 Vulvar and Vaginal Atrophy Therapy Industry Restraints
3 Vulvar and Vaginal Atrophy Therapy Market by Manufacturers
  1. 3.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vulvar and Vaginal Atrophy Therapy Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vulvar and Vaginal Atrophy Therapy Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vulvar and Vaginal Atrophy Therapy Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vulvar and Vaginal Atrophy Therapy Manufacturers, Product Type & Application
  7. 3.7 Global Vulvar and Vaginal Atrophy Therapy Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vulvar and Vaginal Atrophy Therapy Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vulvar and Vaginal Atrophy Therapy Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vulvar and Vaginal Atrophy Therapy Tier 1, Tier 2, and Tier 3
4 Vulvar and Vaginal Atrophy Therapy Market by Type
  1. 4.1 Vulvar and Vaginal Atrophy Therapy Type Introduction
  2. 4.1.1 Vulvar Atrophy Therapy
  3. 4.1.2 Vaginal Atrophy Therapy
  4. 4.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Type
  5. 4.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032)
  7. 4.2.3 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2021-2032)
  8. 4.3 Global Vulvar and Vaginal Atrophy Therapy Revenue by Type
  9. 4.3.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032)
  11. 4.3.3 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2021-2032)
5 Vulvar and Vaginal Atrophy Therapy Market by Application
  1. 5.1 Vulvar and Vaginal Atrophy Therapy Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Ambulatory Surgical Centers
  5. 5.1.4 Others
  6. 5.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Application
  7. 5.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032)
  9. 5.2.3 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2021-2032)
  10. 5.3 Global Vulvar and Vaginal Atrophy Therapy Revenue by Application
  11. 5.3.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032)
  13. 5.3.3 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2021-2032)
6 Global Vulvar and Vaginal Atrophy Therapy Sales by Region
  1. 6.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2021-2032)
  3. 6.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Region (2021-2026)
  4. 6.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region
  1. 7.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region
  2. 7.1.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2021-2026)
  4. 7.1.3 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region (2027-2032)
  5. 7.1.4 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032)
  8. 7.2.2 North America Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032)
  11. 7.3.2 Europe Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vulvar and Vaginal Atrophy Therapy Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Viveve
  2. 8.1.1 Viveve Company Information
  3. 8.1.2 Viveve Business Overview
  4. 8.1.3 Viveve Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Viveve Vulvar and Vaginal Atrophy Therapy Product Portfolio
  6. 8.1.5 Viveve Recent Developments
  7. 8.2 VenusConcept
  8. 8.2.1 VenusConcept Company Information
  9. 8.2.2 VenusConcept Business Overview
  10. 8.2.3 VenusConcept Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 VenusConcept Vulvar and Vaginal Atrophy Therapy Product Portfolio
  12. 8.2.5 VenusConcept Recent Developments
  13. 8.3 ThermiGen LLC
  14. 8.3.1 ThermiGen LLC Company Information
  15. 8.3.2 ThermiGen LLC Business Overview
  16. 8.3.3 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Product Portfolio
  18. 8.3.5 ThermiGen LLC Recent Developments
  19. 8.4 Lutronic
  20. 8.4.1 Lutronic Company Information
  21. 8.4.2 Lutronic Business Overview
  22. 8.4.3 Lutronic Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lutronic Vulvar and Vaginal Atrophy Therapy Product Portfolio
  24. 8.4.5 Lutronic Recent Developments
  25. 8.5 Hologic
  26. 8.5.1 Hologic Company Information
  27. 8.5.2 Hologic Business Overview
  28. 8.5.3 Hologic Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hologic Vulvar and Vaginal Atrophy Therapy Product Portfolio
  30. 8.5.5 Hologic Recent Developments
  31. 8.6 Fotona
  32. 8.6.1 Fotona Company Information
  33. 8.6.2 Fotona Business Overview
  34. 8.6.3 Fotona Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fotona Vulvar and Vaginal Atrophy Therapy Product Portfolio
  36. 8.6.5 Fotona Recent Developments
  37. 8.7 BTL Group of Companies
  38. 8.7.1 BTL Group of Companies Company Information
  39. 8.7.2 BTL Group of Companies Business Overview
  40. 8.7.3 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Product Portfolio
  42. 8.7.5 BTL Group of Companies Recent Developments
  43. 8.8 Almirall
  44. 8.8.1 Almirall Company Information
  45. 8.8.2 Almirall Business Overview
  46. 8.8.3 Almirall Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Almirall Vulvar and Vaginal Atrophy Therapy Product Portfolio
  48. 8.8.5 Almirall Recent Developments
  49. 8.9 Alma Lasers
  50. 8.9.1 Alma Lasers Company Information
  51. 8.9.2 Alma Lasers Business Overview
  52. 8.9.3 Alma Lasers Vulvar and Vaginal Atrophy Therapy Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Alma Lasers Vulvar and Vaginal Atrophy Therapy Product Portfolio
  54. 8.9.5 Alma Lasers Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vulvar and Vaginal Atrophy Therapy Value Chain Analysis
  2. 9.1.1 Vulvar and Vaginal Atrophy Therapy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vulvar and Vaginal Atrophy Therapy Production Mode & Process
  6. 9.2 Vulvar and Vaginal Atrophy Therapy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vulvar and Vaginal Atrophy Therapy Distributors
  9. 9.2.3 Vulvar and Vaginal Atrophy Therapy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst